论文部分内容阅读
目的:探讨保列治联合哈乐治疗良性前列腺增生的临床效果。方法:回顾性分析2009年10月～2011年10月期间我院门诊收治的86例良性前列腺增生患者的病历资料,随机分为两组,其中观察组43例给予口服保列治联合哈乐治疗,对照组43例单给予口服保列治治疗,观察、比较两组患者治疗前后的IPSS评分、前列腺体积、排尿量、残余尿量及尿潴留与血尿的发生率。结果:治疗6个月后,与治疗前相比两组患者的IPSS评分、前列腺体积、排尿量、残余尿量及尿潴留与血尿的发生率均差异性显著,具有统计学意义(P<0.05);观察组的IPSS评分、前列腺体积、排尿量、残余尿量及尿潴留与血尿的发生率均显著优于对照组,组间差异有统计学意义(P<0.01)。两组均未发生尿潴留、前列腺源性血尿、增生引起的肾功能不全、反复泌尿系感染等不良反应。结论:保列治联合哈乐治疗良性前列腺增生疗效显著,可有效稳定前列腺下降体积,缓解下尿路刺激症状,改善最大尿流率,提高患者生活质量。
Objective: To investigate the clinical effect of Proliferation and Harmony in the treatment of benign prostatic hyperplasia. Methods: The clinical data of 86 patients with benign prostatic hyperplasia (BPH) treated in our hospital from October 2009 to October 2011 were retrospectively analyzed. The patients were randomly divided into two groups, of which 43 patients in the observation group were given oral promethazole combined with Halo therapy , 43 cases in the control group were given oral promethazine treatment. The IPSS score, prostate volume, urinary output, residual urine volume, urinary retention and hematuria were compared between the two groups before and after treatment. Results: After 6 months of treatment, IPSS score, prostate volume, urine output, residual urine volume, urinary retention and hematuria were significantly different between the two groups before treatment (P <0.05 ). The IPSS score, prostate volume, urine output, residual urine volume, urinary retention and hematuria in the observation group were significantly better than those in the control group. There was significant difference between the two groups (P <0.01). No urinary retention, prostatic hematuria, renal insufficiency due to hyperplasia, repeated urinary tract infections and other adverse reactions occurred in both groups. Conclusion: Prostate Harmony treatment of benign prostatic hyperplasia significant effect, can effectively stabilize the prostate volume reduction, relieve the symptoms of lower urinary tract irritation, improve the maximum flow rate and improve the quality of life of patients.